Check for updates

OPEN ACCESS

EDITED BY Alessandro De Vita, Scientific Institute of Romagna for the Study and Treatment of Tumors (IRCCS), Italy

REVIEWED BY Silvia Vanni, IRST, Italy Federica Recine, Azienda Ospedaliera San Giovanni Addolorata, Italy

*CORRESPONDENCE Qi Zeng Syfycszq@163.com

RECEIVED 29 January 2024 ACCEPTED 06 March 2024 PUBLISHED 25 March 2024

CITATION

Wu J and Zeng Q (2024) Nomogram to predict prognosis of head and neck rhabdomyosarcoma patients in children and adolescents. *Front. Oncol.* 14:1378251. doi: 10.3389/fonc.2024.1378251

COPYRIGHT

© 2024 Wu and Zeng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Nomogram to predict prognosis of head and neck rhabdomyosarcoma patients in children and adolescents

Jinwen Wu^{1,2} and Qi Zeng^{1*}

¹Department of Ultrasound, The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China, ²Gannan Medical University, Ganzhou, Jiangxi, China

Purpose: This study aims to explore the prognostic factors of head and neck rhabdomyosarcoma (HNRMS) in children and adolescents and construct a simple but reliable nomogram model for estimating overall survival (OS) of patients.

Methods: Data of all HNRMS patients during 2004–2018 were identified from the Surveillance, Epidemiology, and End Result database. Kaplan–Meier method was performed to calculate OS stratified by subgroups and comparison between subgroups was completed by log-rank test. Univariate and multivariate Cox regressions analysis were employed for identifying independent predictors, which subsequently were used for a predictive model by R software, and the efficacy of the model was evaluated by applying receiver operating curve (ROC), calibration and decision curve analysis (DCA).

Results: A total of 446 patients were included in the study. The 1-, 3-, and 5-year OS rate of the whole cohort was 90.6%, 80.0%, and 75.5%, respectively. The results of univariate and multivariate Cox regression analysis indicated that the primary site in parameningeal region, alveolar RMS histology, M1 stage, IRS stage 4, surgery, and chemotherapy were significant prognostic factors (all *P*<0.05). The performance of nomogram model was validated by discrimination and calibration, with AUC values of 1, 3, and 5 years OS of 0.843, 0.851, and 0.890, respectively.

Conclusion: We constructed a prognostic nomogram model for predicting the OS in HNRMS patients in children and adolescents and this model presented practical and applicable clinical value to predict survival when choosing treatment strategies.

KEYWORDS

rhabdomyosarcoma, head and neck, prognostic survival analysis, nomogram, SEER

Abbreviations: RMS, rhabdomyosarcoma; STS, soft tissue sarcoma; HNRMS, head and neck rhabdomyosarcoma; OR, orbital RMS; PR, parameningeal RMS; NOPR, non-orbital-parameningeal RMS; IRS, Intergroup Rhabdomyosarcoma Study; OS, overall survival; SEER, Surveillance, Epidemiology, and End Result; ROC, receiver operating curve; AUC, area under the curve; DCA, decision curve analysis.



Introduction

Rhabdomyosarcoma (RMS) is a rare but aggressive malignant tumor originating from the embryonic mesenchyme of the rhabdomyosarcoma tissue (1) and is the most common soft tissue sarcoma (STS) in children and adolescents (2), accounting for about 4%-5% of cancers in the pediatric population (3). Although RMS can occur anywhere in the body, 40% of primary lesions originate in the head and neck region that can be further classified as the orbital RMS (OR), parameningeal RMS (PR) and non-orbitalparameningeal RMS (NOPR) (4-6). RMS is characterized by unclear prognostic factors and poor survival, it is reported that high-risk RMS and recurrent disease have 5-year survival rates of lessen 30% and 17%, respectively (7). However, the overall survival (OS) rate of patients has been increased through better staging, risk grouping, improved localized treatments, and better supportive care after The Intergroup Rhabdomyosarcoma Study (IRS) was established in the United States in 1972 (8, 9). The treatment method of RMS is multimodal, involves multi-agent systemic chemotherapy, along with surgical resection of the tumor with or without addition of the radiation therapy for control of local lesion (10). The identification of prognostic factors for RMS may help with optimizing treatment protocols.

A nomogram is a graphical tool for displaying the predicted value of individual survival based on significant variables produced by multivariate regression analysis briefly and intuitively (11, 12); currently, it has been widely used in disease prediction of malignant tumors such as laryngeal carcinoma and lung cancer etc (13–15). There are also some nomograms that have been constructed and proven to be beneficial in the management of RMS (16–18), and they present obvious advantages such as improved predictive accuracy, robustness, and usability, all of which increase their potentials in clinical practices. As a result, nomograms have been proposed as alternative methods, or perhaps new standard, to guide the management of cancer patients (19, 20). However, there is still a lack of nomogram model to predict the survival probability of head and neck rhabdomyosarcoma (HNRMS) patients in children and adolescents, which may be attributed to limited cases reports and small case studies in each single institution.

In this study, we analyzed the demographic, clinical characteristics and treatment strategies for predicting OS of HNRMS patients in children and adolescence by using populationbased data recorded in the Surveillance, Epidemiology, and End Results (SEER), with the purpose of providing clinicians and patients with a simple but effective clinical tool to predict survival.

Patients and methods

Data collection

SEER-State software (version 8.4.2; http://seer.cancer.gov) was used to download RMS data from SEER database. Inclusion criteria were as follows: (1) primary tumor location in head and neck (anatomical codes: C00.0-C14.0, C 44.1-C44.4, C49.0, C69.0-C72.0); (2) year of diagnosis from 2004 to 2018; (3) age at diagnosis under 18 years old (4) histologic types were RMS (ICD-O-3 codes: 8900/3, 8901/3, 8902/3, 8910/3, 8912/3, 8920/3, and 8921/3). Exclusion criteria were listed as follows: (1) diagnosis made by autopsy or death certificate rather than pathohistological biopsy; (2) incomplete or unknown survival information. The original data for this study were obtained from publicly available database, and the present study complies with the principles of the Declaration of Helsinki. As such, this study was exempt from ethics review by the ethics committee.

Variable definitions and end point

Variable definitions and information extracted from SEER database included patient ID, gender, age at diagnosis, primary sites, histology, TNM stage, tumor size, surgery, radiotherapy, and chemotherapy. Tumor primary site was classified into OR, PR, and NOPR; PR includes nasopharynx, nasal cavity, parapharyngeal region, sinuses, pterygopalatine fossa, middle ear, and mastoid process, while NOPR mainly consists of tongue, palate, and all other head and neck regions except obtial region (21). Histological types were classified into embryonal, alveolar, and other types. Tumor size was classified as ≤ 5 cm and >5 cm. RMS staging was based on the pre-treatment IRS staging system, which was shown in Table 1. OS was defined as the number of survival months that HNRMS patients to death from any cause at the end of follow-up, and the end point event was standardized by death from any cause, if not, censored was recorded.

Statistical analysis

Statistical analysis and graphs were finished by the R software (version 4.1.3; http://www.rproject.org). Continuous variables were expressed as median with interquartile range, while categorical variables were expressed as number (percentage). Variables selected by SEER database were preliminarily analyzed by univariate Cox regression, and variables with P < 0.05 were incorporated into multivariate Cox regression for identifying independent prognostic factors. The Kaplan-Meier method was performed to compare the OS. A nomogram prediction model was constructed based on by the results of multivariate Cox regression analysis to predict 1-, 3-, and 5-year OS of HNRMS in children and adolescents. The Bootstrap 1000 resampling method was used for calibration analysis of the nomogram. The discrimination ability was evaluated by receiver operating characteristic (ROC) with area under the curve (AUC), and the consistency was evaluated by calibration curves. Decision curve analysis (DCA) was used for evaluating clinical feasibility. The P < 0.05 was considered as statistical significance.

Results

Demographic and clinical characteristics of patients

According to the inclusion and exclusion criteria, 446 patients with HNRMS in children and adolescents were identified between 2004 and 2018 from the SEER database. Tumor primary site were OR in 110 cases (24.6%), PR in 82 cases (18.4%), and NOPR in 254 cases (57.0%). The embryonal was the most common histological type accounting for 65.9%, followed by the alveolar (22.7%), and other types (11.4%). As for the RMS staging:T1 (23.8%) and T2 (38.3%); N0 (60.8%) and N1(10.1%); M0 (59.9%) and M1 (14.3%); 53.1% of tumor size was less than 5 cm and 29.4% of which was more than 5 cm; patients were 309 cases (69.3%) in IRS stage 1, 66 cases (14.8%) in stage 4. In terms of treatment, the majority of patients received surgical treatment (94.4%) and more than half of patients received radiotherapy (26.0%). The demographics and clinical characteristics were shown in Table 2.

Survival analysis of different prognosis

The median follow-up time for the entire cohort was 54 months (interquartile range: 22-111 months). Less than half of patients (102, 22.8%) died during the follow-up time, and the 1-, 3-, and 5year OS of patients were 90.6%, 80.0%, and 75.5%, respectively. To identify prognostic factors associated with OS in patients with HNRMS in children and adolescents, we conducted univariate and multivariate Cox regression analysis (Table 3). The results of univariate Cox regression analysis showed that the primary site in PR, alveolar RMS, M1 stage, tumor size more than 5 cm, IRS stage 4, surgery, radiotherapy, and chemotherapy were significant prognostic factors for OS (all P < 0.05), in which the primary site in PR, alveolar RMS, M1 stage, tumor size more than 5 cm as well as IRS stage 4 were associated with poor OS, while performing surgical, radiotherapy and chemotherapy treatment were associate with favorable outcome of OS. The results of multivariate Cox regression analysis showed that primary site in PR, alveolar RMS, M1 stage, IRS stage 4 were independent risk prognostic factors; surgery and chemotherapy were protective prognostic factors for HNRMS patients (Figures 1A-H).

TABLE 1 IRS staging system of rhabdomyosarcoma patients before treatment.

IRS stage	Primary site	T stage	Size(cm)	N stage	M stage
1	А	T1 or T2	≤5 or >5	N0, N1	M0
2	В	T1 or T2	≤5	N0	M0
3	В	T1 or T2	≤5 or >5	N0, N1	M0
4	A or B	T1 or T2	≤5 or >5	N0	M1

A refers to primary site in head and neck with favorable prognosis (OR or NOPR) and B refers to unfavorable prognosis (PR). T stage includes T1 and T2, T1: tumor was confined to primary organs or tissues; T2: tumor involves contiguous organs or structures. N stage includes N0 and N1, N0: no clinical or radiographic evidence of involvement of regional lymph nodes; N1: clinical or radiographic evidence of regional lymph node involvement. M stage includes M0 and M1, M0: no distant metastases on clinical, radiographic, or bone marrow assessment, M1: evidence of distant metastasis.

TABLE 2 Patient demographics and clinical characteristics.

Characteristics	Category	Number of cases	F (%)/M (P25, P75)
Gender			
	male	238	53.4
	female	208	46.6
Age			6 (4, 10)
Primary site			
	OR	110	24.6
	PR	82	18.4
	NOPR	254	57.0
Histology			
	Embryonal	294	65.9
	Alveolar	101	22.7
	Other	51	11.4
T stage			
	T1	106	23.8
	T2	171	38.3
	Unknown	169	37.9
N stage			
	N0	271	60.8
	N1	45	10.1
	Unknown	130	29.1
M stage			
	M0	267	59.9
	M1	64	14.3
	Unknown	115	25.8
Tumor size (cm)			
	≤5cm	237	53.1
	>5cm	131	29.4
	Unknown	78	17.5
IRS stage	1	309	69.3
	4	66	14.8
	Unknown	71	15.9
Surgery			
	Yes	421	94.4
	No/ Unknown	25	5.6
Radiotherapy			
	Yes	116	26.0
	No/ Unknown	330	74.0

(Continued)

TABLE 2 Continued

Characteristics	Category	Number of cases	F (%)/M (P25, P75)
Chemotherapy			
	Yes	289	64.8
	No/ Unknown	157	35.2

Construction and validation of nomogram model

According to the results of multivariate analysis, tumor primary site, histology, M stage, IRS stage, surgery, and chemotherapy were associated with OS (all P < 0.05). We incorporated above six factors into constructing 1-, 3-, and 5-year nomogram of OS rate (Figure 2), and the point corresponding to each variable was projected to the scoring scale; finally, the scores of each variable were summed up to get the total scores. The AUC values of 1, 3, and 5 years OS were 0.843, 0.851, 0.890, respectively (Figure 3). The calibration curves shown in (Figures 4A-C) presented a good consistency between the nomogram predicted and actually observed 1, 3, and 5 years OS, which indicated that the predictive efficacy of the model was high. The decision curve analysis (DCA) was applied to render the clinical benefit value to the nomogram using the training cohort. The results showed that the prediction model had a high-clinical benefit value, good ability to assess the prognosis of patients with HNRMS, and good clinical practicability (Figure 5).

Discussion

The tumor primary site was classified into favorable and unfavorable based on criteria used for staging pediatric tumors (21). In terms of HNRMS, favorable site refers to OR and NOPR, while unfavorable refers to PR. In our study, both univariate (HR: 7.85, 95% CI: 3.24–19.03, P < 0.001) and multivariate Cox regression (HR: 3.32, 95% CI: 1.09–10.13, P = 0.035) showed that PR was associated with poor OS, which is consistent with previous studies (22, 23). This may be due to the fact that the PR is close to the intracranial area and could not be completely removed (24). Furthermore, compared with superficial sites such as OR, PR is less likely to be detected, making it impossible to find and diagnose the tumor in time, and the lesion may have distant metastasis in early stage, which may metastasize first to the lungs or the bones (25). Orbital RMS affects eye movements at an early stage, so it is usually detected earlier and has a better prognosis.

In our study, the proportion of tumor size more than 5 cm was about 29.4%, which was lower than 51% in the IRS-IV study (9), 47.2% in the study of Ma et al. (26), and 75.5% reported by the Japanese researchers Hosoi et al. (27); this may be attributed to HNRMS limited growth space. Unsal et al. (28) and Dantonello et al. (29) reported that tumor size is a risk factor for poor survival. This is consistent with our study finding that a larger tumor was an adverse prognostic factor in HNRMS patients. Studied showed that

<table-container>VariablesIR (95% Cl)pIR (95% Cl)pGenderGenderImageRefrace0.3 (92-4.04)0.541Parale0.3 (92-4.04)0.5411Age0.3 (92-4.04)0.5211Age0.3 (92-4.04)0.5211Age0.3 (92-4.04)0.5211Age0.3 (92-4.04)0.5211Age0.3 (92-10.04)0.5211Age0.53 (224-19.03)0.601.63 (0.57.05)0.37Age0.53 (224-19.03)0.601.63 (0.57.05)0.37Hotopy0.53 (224-19.03)0.601.63 (0.57.05)0.37Hotopy0.73 (224-19.03)0.601.63 (0.57.05)0.37Hotopy0.740.740.740.750.75Hotopy0.740.740.740.750.75Hotopy0.740.740.740.740.74Hotopy0.740.740.740.740.74Hotopy0.740.740.740.740.74Hotopy0.740.740.740.740.74Hotopy0.740.740.740.740.74Hotopy0.740.740.740.740.74Hotopy0.740.740.740.740.74Hotopy0.740.740.740.740.74Hotopy0.740.740.740.740.74<th>Variables</th><th></th><th colspan="2">OS Univariate</th><th colspan="2">OS Multivariate</th></table-container>	Variables		OS Univariate		OS Multivariate		
IndexReferenceIndexReferenceIndexIndexIndexAgeImage0.301.010.31.010.31.01ImagePrimary siteImage0.301.010.31.01.010.31.01Primary siteImage0.301.010.31.01.010.31.01Primary site0.31.01.010.31.01.010.31.010.31.01Primary site0.31.01.010.31.01.010.31.010.31.01Primary site0.31.01.010.31.010.31.010.31.01Primary site0.31.01.010.31.010.31.01 <th>variables</th> <th></th> <th>HR (95% CI)</th> <th>p</th> <th>HR (95% CI)</th> <th>p</th>	variables		HR (95% CI)	p	HR (95% CI)	p	
ImageParticleParticleParticleParticleAgeParticle	Gender						
<table-container>AgeImageSequeSequeSequePirany sitePirany siteImageReferenceRef</table-container>		Male	Reference				
Primary siteImage and the second of the second		Female	0.93 (0.59-1.48)	0.765			
IndexRefereRefereRefereRefereRefereRef76,324.93,036,0932 (1,94.93,10)32 (1,94.93,10)32 (1,94.93,10)Hetcolog32 (1,94.93,10)1,0401,04034 (1,94.93,10)34 (1,94.93,10)Hetcolog888881,040Ref8881,040,1001,0401,040Ref260,140,1000,1011,0111,011Ref111,011,1001,0111,0111,011Ref111,011,1001,0111,0111,011Ref111,011,1001,0111,0111,011Ref111,011,1001,0111,0111,011Ref111,011,1001,0111,0111,011Ref111,011,1001,0111,0111,011Ref111,011,1001,0111,0111,011Ref111,011,1001,0111,0111,011Ref111,011,1001,0111,0111,011Ref111,011,1001,0111,0111,011Ref111,011,1001,0111,0111,011Ref111,011,1001,0111,0111,011Ref111,011,1001,0111,0111,011Ref1111,0111,0111,011 <td>Age</td> <td></td> <td>0.99 (0.94-1.05)</td> <td>0.82</td> <td></td> <td></td>	Age		0.99 (0.94-1.05)	0.82			
ImageRefereStateStateStateStateStateHereStateStateStateStateStateHistoryState	Primary site						
IndexSequeSequeSequeSequeSequeSequeSequeHistologyEdinyaniaReferaceIReferaceISeque <td< td=""><td></td><td>OR</td><td>Reference</td><td></td><td>Reference</td><td></td></td<>		OR	Reference		Reference		
HistologyMethodNetworkNetworkNetworkInterportReference		PR	7.85 (3.24-19.03)	<0.001*	3.32 (1.09-10.13)	0.035*	
Index and the series of the		NOPR	3.52 (1.49-8.31)	0.004	1.46 (0.57-3.75)	0.427	
IndexActionActionActionActionActionActionActionActionActionActionActionTataeInformKerenceInformAction	Histology						
IndexIndexIndexIndexIndexIndexIndexOdd (23-1a)0Odd (23-1a)0		Embryonal	Reference		Reference		
ratageImageImageImageImage17Reference <td></td> <td>Alveolar</td> <td>2.67 (1.67-4.28)</td> <td>0.001*</td> <td>1.82 (1.10-3.02)</td> <td>0.020*</td>		Alveolar	2.67 (1.67-4.28)	0.001*	1.82 (1.10-3.02)	0.020*	
IndexRefereIndexRefereIndexIndexIndex1204040120055000Nanom01060130752000Natage000000NalonRefere00000100.80301800.9030000Natage000000Natage000000Natage000000Natage000000Natage000000Natage000000Natage000000Natage000000Natage000000Natage000000Natage000000Natage000000Natage000000Natage000000Natage000000Natage000000Natage000000Natage000000 </td <td></td> <td>Other</td> <td>0.64 (0.23-1.80)</td> <td>0.398</td> <td>0.82 (0.46-2.37)</td> <td>0.715</td>		Other	0.64 (0.23-1.80)	0.398	0.82 (0.46-2.37)	0.715	
IndexIndexIndexIndexIndexVarianceVarianceVarianceVarianceVarianceNatageNatageIndexIndexIndexIndexNatageSingaseSingaseSingaseIndexIndexNatageSingaseSingaseSingaseIndexIndexMatageSingaseSingaseSingaseSingaseIndexMatageSingaseSingaseSingaseSingaseSingaseMatageSingaseSingaseSingaseSingaseSingaseMatageSingaseSingaseSingaseSingaseSingaseMatageSingaseSingaseSingaseSingaseSingaseMatageSingaseSingaseSingaseSingaseSingaseMatageSingaseSingaseSingaseSingaseSingaseMatageSingaseSingaseSingaseSingaseSingaseMatageSingaseSingaseSingaseSingaseSingaseMatageSingaseSingaseSingaseSingaseSingaseMatageSingaseSingaseSingaseSingaseSingaseMatageSingaseSingaseSingaseSingaseSingaseMatageSingaseSingaseSingaseSingaseSingaseMatageSingaseSingaseSingaseSingaseSingaseMatageSingaseSingaseSingaseSingaseSingaseMata	T stage						
Induction 		T1	Reference				
N stageVertical Section of Sectin of Section of Sect		T2	0.84 (0.46-1.52)	0.565			
IndexReferenceIndexReferenceIndexIndexNanowa0.830.038.1.890.693.000.693.000.100.000.100.00Nanowa0.12(0.72.09)0.410.100.000.100.000.100.00MatageNanowaReference0.01*0.20(1.03.46.90)0.01*Manowa0.20(1.03.46.90)0.01*0.01*0.90.03.21.400.01*Manowa1.78(0.93.34.00)0.01*0.89(0.37.21.40)0.95Mutanowa1.78(0.93.34.00)0.01*0.89(0.37.21.40)0.95Mutanowa1.78(0.93.34.00)0.01*0.89(0.37.21.40)0.95Mutanowa1.78(0.93.34.00)0.01*0.89(0.37.21.40)0.95Mutanowa1.78(0.93.34.00)0.01*0.89(0.37.21.40)0.95Mutanowa1.78(0.93.34.00)0.01*0.89(0.37.21.40)0.89Mutanowa1.89(0.93.21.40)0.91*1.20(0.22.80)0.81Mutanowa1.99(0.36.67.20)0.01*1.20(0.32.80.40)0.49Mutanowa1.99(0.36.67.20)0.40*1.20(0.32.80.40)0.41Mutanowa1.89(0.81.36.10.40)0.610*1.20(0.32.80.40)0.12*Mutanowa1.80(0.81.40.40)1.610*1.610*1.610*Mutanowa1.80(0.81.40.40)1.610*1.610*1.610*Mutanowa1.810.40.401.610*1.610*1.610*Mutanowa1.810.40.401.610*1.610*1.610*Mutanowa1.610*1.610*1.610*1.610* <td></td> <td>Unknown</td> <td>1.09 (0.60-1.96)</td> <td>0.785</td> <td></td> <td></td>		Unknown	1.09 (0.60-1.96)	0.785			
IndexNameNameNameNameName124074.09043124074.09041124074.09MatageMatageNameNameSerenceSerence124074.09ManonNaferenceNameSerence041*NameNameSerenceSerence041*NameNameNameSerence041*NameNameNameSerence041*NameNameNameSerence041*NameSerenceSerenceSerenceSerenceNameSerenceSerenceSerenceSerenceNameSerenceSerenceSerenceSerenceNameSerenceSerenceSerenceSerenceNameSerence<	N stage						
IndexIndexIndexIndexIndexVarbornVarborn0.41IndexIndexMatageManonReferaceReferaceReferaceIndexManonSa3 (484.1387)0.001*2.01 (0.34.69)0.01*Unknown1.78 (0.95.3.34)0.01*0.89 (0.37.2.14)0.975Tumor sizeVarborn0.01*0.89 (0.37.2.14)0.975SamonSamon0.01*0.89 (0.37.2.14)0.975UnknownSamon0.01*0.89 (0.37.2.14)0.975SamonSamon0.01*0.89 (0.37.2.14)0.975SamonSamon0.01*0.89 (0.37.2.14)0.975SamonSamon0.01*0.89 (0.37.2.14)0.975SamonSamon0.01*0.89 (0.37.2.14)0.975SamonSamon0.01*0.89 (0.37.2.14)0.975SamonSamon0.01*0.9140.975SamonSamon0.01*0.9140.9140.914SamonSamon0.01*0.9140.9140.914SamonSamon0.01*0.9140.9140.914SamonSamonSamon0.9140.9140.914SamonSamon0.9140.9140.9140.914SamonSamonSamon0.9140.9140.914SamonSamonSamon0.9140.9140.914SamonSamonSamonSamon0.9140.914Samon <td< td=""><td></td><td>N0</td><td>Reference</td><td></td><td></td><td></td></td<>		N0	Reference				
M stage Note of the service of the servic		N1	0.85 (0.38-1.89)	0.693			
ÍndMoRefereIndexRefereRefereMaS2 (4.8-13.67)0.0012.0 (1.0.4.69)0.014IndexTardore0.0748.9 (0.37.2.14)0.75Tunor sizeSemanSemanSemanSemanScmSemanSemanSemanSemanSemanIndexSemanSemanSemanSemanSemanIndexSemanSemanSemanSemanSemanIndexSemanSemanSemanSemanSemanIndexSemanSemanSemanSemanSemanIndexSemanSemanSemanSemanSemanIndexSemanSemanSemanSemanSemanIndexSemanSemanSemanSemanSemanIndexSemanSemanSemanSemanSemanIndexSemanSemanSemanSemanSemanIndexSemanSemanSemanSemanSemanIndexSemanSemanSemanSemanSemanIndexSemanSemanSemanSemanSemanIndexSemanSemanSemanSemanSemanIndexSemanSemanSemanSemanSemanIndexSemanSemanSemanSemanSemanIndexSemanSemanSemanSemanSemanIndexSemanSemanSemanSemanSeman <td< td=""><td></td><td>Unknown</td><td>1.24 (0.74-2.09)</td><td>0.41</td><td></td><td></td></td<>		Unknown	1.24 (0.74-2.09)	0.41			
IndexAlexan (Alexan (Alexan))Alexan (Alexan)Alexan (Alexan)IndexJag (Alexan)Alexan (Alexan)Alexan (Alexan)Alexan (Alexan)IndexJag (Alexan)Alexan (Alexan)Alexan (Alexan)Alexan (Alexan)IndexSemaReferenceIlexan (Alexan)Alexan (Alexan)Alexan (Alexan)IndexSemaAlexan (Alexan)Alexan (Alexan)Alexan (Alexan)Alexan (Alexan)IndexAlexan (Alexan)Alexan (Alexan)Alexan (Alexan)Alexan (Alexan)Alexan (Alexan)IndexIndexAlexan (Alexan)Alexan (Alexan)Alexan (Alexan)Alexan (Alexan)IndexIndexAlexan (Alexan)Alexan (Alexan)Alexan (Alexan)Alexan (Alexan)IndexIndexAlexan (Alexan)Alexan (Alexan)Alexan (Alexan)Alexan (Alexan)Index	M stage						
IndexIndexIndexIndexIndexUnknown1.78 (0.95-3.34)0.7430.89 (0.37-2.14)0.753TUTON SizeTutor sizeIndexSemanReferaceIndexIndexIndexSeman0.99 (0.36-6.72)0.001*1.53 (0.82-2.84)0.80IndexJay (0.64-3.05)0.4041.20 (0.52-2.86)0.649IndexIndexJay (0.64-3.05)0.4041.20 (0.52-2.86)0.649IndexIndexSeraceIndexIndexIndexIndexIndexSeraceIndex <td></td> <td>M0</td> <td>Reference</td> <td></td> <td>Reference</td> <td></td>		M0	Reference		Reference		
Tumor size Image: Second Control of Second C		M1	8.23 (4.88-13.87)	<0.001*	2.20 (1.03-4.69)	0.041*	
Image: state		Unknown	1.78 (0.95-3.34)	0.074	0.89 (0.37-2.14)	0.795	
Image: Marcine and	Tumor size						
Index Instruction <th< td=""><td></td><td>≤5cm</td><td>Reference</td><td></td><td>Reference</td><td></td></th<>		≤5cm	Reference		Reference		
IRS stage Reference Reference Reference 0.01* 2.53 (1.23-5.22) 0.012* 1 0.43 (0.13-1.41) 0.166 0.28 (0.07-1.04) 0.058 Surgery 1 No/Unknown Reference Reference 0.01* 1 0.33 (0.13-0.41) 0.166 0.28 (0.07-1.04) 0.058 Surgery Yes 0.23 (0.13-0.41) 0.001* 0.52 (0.27-0.99) 0.048*		>5cm	3.99 (2.36-6.72)	<0.001*	1.53 (0.82-2.84)	0.180	
Instruction Reference Reference 1 Reference Reference Reference 1 Reference Statistication Reference Reference 1 Reference Reference Statistication Statistication Statistication 1 Reference Reference Reference Statistication Statistication 1 No/Unknown Reference Instruction Reference Reference 1 No/Unknown Reference Instruction Statistication Statistication 1 No/Unknown Reference Instruction Statistication Statistication Statistication 1 No/Unknown <td< td=""><td></td><td>Unknown</td><td>1.39 (0.64-3.05)</td><td>0.404</td><td>1.22 (0.52-2.86)</td><td>0.649</td></td<>		Unknown	1.39 (0.64-3.05)	0.404	1.22 (0.52-2.86)	0.649	
A 8.35 (5.18-13.64) <0.001* 2.53 (1.23-5.22) 0.012* Unknown 0.43 (0.13-1.41) 0.166 0.28 (0.07-1.04) 0.058 Surgery No/Unknown Reference Reference 0.01* 0.048* Yes 0.23 (0.13-0.41) 0.001* 0.52 (0.27-0.99) 0.048*	IRS stage						
Image: Constraint of the state of		1	Reference		Reference		
Surgery No/Unknown Reference Reference 0.001* 0.52 (0.27-0.99) 0.048* Radiotherapy Image: Contract of the second of th		4	8.35 (5.18-13.64)	<0.001*	2.53 (1.23-5.22)	0.012*	
No/Unknown Reference Reference Yes 0.23 (0.13-0.41) <0.001*		Unknown	0.43 (0.13-1.41)	0.166	0.28 (0.07-1.04)	0.058	
Yes 0.23 (0.13-0.41) <0.001* 0.52 (0.27-0.99) 0.048* Radiotherapy Image: Contract of the second	Surgery						
Radiotherapy		No/Unknown	Reference		Reference		
		Yes	0.23 (0.13-0.41)	<0.001*	0.52 (0.27-0.99)	0.048*	
No/Unknown Reference Reference	Radiotherapy						
		No/Unknown	Reference		Reference		

TABLE 3 Univariate and multivariate Cox regression analysis of OS in head and neck rhabdomyosarcoma patients among children and adolescents.

(Continued)

TABLE 3 Continued

Variables		OS Univariate		OS Multivariate		
		HR (95% CI)	p	HR (95% CI)	p	
Radiotherapy						
	Yes	0.54 (0.33-0.88)	0.013*	1.42 (0.81-2.50)	0.221	
Chemotherapy						
	No/Unknown	Reference		Reference		
	Yes	0.26 (0.13-0.49)	<0.001*	0.45 (0.22-0.93)	0.032*	

* P value is significant.

tumor size with more than 5 cm was independent risk predictor for survival and local treatment failure (30); the result of univariate Cox regression showed that tumor size with more than 5cm was a risk factor for prognosis in children and adolescence (HR: 3.99, 95% CI: 2.36–6.72, P < 0.001).

RMS was divided into four subgroups: embryonal, alveolar, pleomorphic, and spindle cell/sclerosing RMS, according to the World Health Organization (WHO) classification system, of which embryonal was the most common subtype (31), embryonal RMS had a clearly more favorable clinical prognosis than alveolar type,

which was observed to occur at an earlier age and associated with better prognosis (32, 33). Alveolar RMS was common in the muscle of the trunk and limb extremities and presented as a poor prognosis (32, 34, 35), studies showed that microarray-based gene expression profiling showed that PAX-FOXO1 fusion gene-positive alveolar RMS had a worse biological behavior than PAX-FOXO1 fusion gene-negative (36, 37). With this, it was evident that FOXO1 fusion status was an important prognostic factor and has replaced pathologic staging in RMS risk stratification in recent years (38, 39). In our study, univariate (HR: 2.67, 95% CI: 1.67–4.28, P <



FIGURE 1

Kaplan-Meier curves of overall survival stratified by (A) Primary site, (B) Histology, (C) M stage, (D) Tumor size, (E) IRS stage, (F) Surgery, (G) Radiotherapy, (H) Chemotherapy.







0.001) and multivariate Cox regression (HR: 1.82, 95% CI: 1.01– 3.02, P = 0.020) showed that alveolar RMS was associated with poorer OS than embryonal RMS, which is consistent with previous research (40). Distant metastasis of RMS was found to be associated with worse survival; a study conducted by Turner and Richmon (41) found that patients with localized and regional disease had a higher 5-year survival rate than patients with distant metastasis (92.4%,



60.1%, vs. 36.6%), and the HR values were 0.15 and 0.37, respectively. Our results are consistent with Turner and his partner' findings with the data of univariate Cox regression (HR: 8.23, 95% CI: 4.88–13.87, P < 0.001) and multivariate Cox regression (HR: 2.20, 95% CI: 1.03-4.69, P = 0.041). In addition, exiting literature suggested that tumors of parameningeal sites present advanced stage; they tended to invade distant tissues and organs (34, 42). As mentioned, embryonal RMS occurred with localized disease and in children at an earlier age. On the other hand, alveolar RMS presented most commonly with distant metastasis as well as in adolescents.

Surgical treatment was often consider as a critical treatment means for improving survival of RMS patients (43); surgeons tended to perform radical resection to remove tumor as well as its adjacent tissues and lymph nodes. However, expansion of the surgical scope in pursuit of negative margins would destroy important structures and functions for HNRMS in children and adolescents. Furthermore, tumor sites in dangerous site, such as intracranial extension, bony erosion of cranial base, or cranial nerve palsy, had increased tremendously surgical feasibility (9). The use of radiation and chemotherapy therapy was also found to be effective in improving survival (40, 41); studies showed that radiotherapy combined with chemotherapy is primary means for patients with unresectable primary tumors after initial treatment (44, 45). Our study showed that surgery, radiotherapy, and chemotherapy were all effective treatment methods for HNRMS in children and adolescences (P < 0.001, P = 0.013, P < 0.001, respectively).

There are a few limitations of this study. First, there are several editions of TNM stage, which could have an affection on IRS stage. Second, the SEER database lacks information on laboratory tests, specific radiotherapy and chemotherapy regimens, and comorbidities; however, they also play a critical role in prognosis of HNRMS (46, 47). Szkandera et al. (48) demonstrated a decreased lymphocyte/monocyte ratio (LMR) represents a novel independent poor prognostic factor in STS patients. Fausti et al. (49) also drew

consistent conclusions that LMR is a specific predictor of Trabectedin efficacy and could be useful in daily clinical practice. Moreover, they highlighted a possible correlation between LMR levels and the percentage of intratumoral macrophages. Finally, this is a retrospective study, and the survival outcomes reported in SEER database are associated with different treatment guidelines, which are different from every era. Thus, selection bias could not be avoided.

Conclusion

A prognostic nomogram model was constructed for predicting the probability of survival in HNRMS in children and adolescents, and this model presented practical and applicable clinical value to predict survival when choosing treatment strategies.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

Author contributions

JW: Data curation, Software, Visualization, Writing – original draft, Writing – review & editing. QZ: Funding acquisition, Resources, Supervision, Writing – original draft, Writing – review & editing.

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by Youth Project of National Natural Science Foundation of China (No. 82102277) and Regional Project of National Natural Science Foundation of China (No. 81960298).

Acknowledgments

We are all grateful to the SEER database for approving the registration and uploading clinical information.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

References

1. Lee RJ, Lee KK, Lin T, Arshi A, Lee SA, Christensen RE. Rhabdomyosarcoma of the head and neck: impact of demographic and clinicopathologic factors on survival. *Oral Surg Oral Med Oral Pathol Oral Radiol.* (2017) 124:271–9. doi: 10.1016/ j.0000.2017.05.507

2. Pappo AS, Shapiro DN, Crist WM, Maurer HM. Biology and therapy of pediatric rhabdomyosarcoma. J Clin Oncol. (1995) 13:2123–39. doi: 10.1200/jco.1995.13.8.2123

3. Collignon C, Carton M, Brisse HJ, Pannier S, Gauthier A, Sarnacki S, et al. Soft tissue sarcoma in children, adolescents and young adults: Outcomes according to compliance with international initial care guidelines. *Eur J Surg Oncol.* (2020) 46:1277–86. doi: 10.1016/j.ejso.2019.11.518

4. Casey DL, Wexler LH, Wolden SL. Worse outcomes for head and neck rhabdomyosarcoma secondary to reduced-dose cyclophosphamide. *Int J Radiat Oncol Biol Phys.* (2019) 103:1151–7. doi: 10.1016/j.ijrobp.2018.11.049

5. Glosli H, Bisogno G, Kelsey A, Chisholm JC, Gaze M, Kolb F, et al. Nonparameningeal head and neck rhabdomyosarcoma in children, adolescents, and young adults: Experience of the European paediatric Soft tissue sarcoma Study Group (EpSSG) - RMS2005 study. *Eur J Cancer*. (2021) 151:84–93. doi: 10.1016/ j.ejca.2021.04.007

6. Merks JH, De Salvo GL, Bergeron C, Bisogno G, De Paoli A, Ferrari A, et al. Parameningeal rhabdomyosarcoma in pediatric age: results of a pooled analysis from North American and European cooperative groups. *Ann Oncol.* (2014) 25:231–6. doi: 10.1093/annonc/mdt426

7. Shern JF, Yohe ME, Khan J. Pediatric rhabdomyosarcoma. Crit Rev Oncog. (2015) 20:227–43. doi: 10.1615/CritRevOncog.v20.i3-4

8. Maurer HM, Beltangady M, Gehan EA, Crist W, Hammond D, Hays DM, et al. The Intergroup Rhabdomyosarcoma Study-I. A final report. *Cancer*. (1988) 61:209–20. doi: 10.1002/1097-0142(19880115)61:2<209::aid-cncr2820610202>3.0.co;2-l

9. Crist WM, Anderson JR, Meza JL, Fryer C, Raney RB, Ruymann FB, et al. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J Clin Oncol. (2001) 19:3091–102. doi: 10.1200/jco.2001.19.12.3091

10. Skapek SX, Ferrari A, Gupta AA, Lupo PJ, Butler E, Shipley J, et al. Rhabdomyosarcoma. Nat Rev Dis Primers. (2019) 5:1. doi: 10.1038/s41572-018-0051-2

11. Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. Nomograms in oncology: more than meets the eye. *Lancet Oncol.* (2015) 16:e173–80. doi: 10.1016/S1470-2045 (14)71116-7

12. Ohori Tatsuo G, Riu Hamada M, Gondo T, Hamada R. [Nomogram as predictive model in clinical practice]. Gan To Kagaku Ryoho. (2009) 36:901-6.

13. Zhang YF, Shen YJ, Huang Q, Wu CP, Zhou L, Ren HL. Predicting survival of advanced laryngeal squamous cell carcinoma: comparison of machine learning models and Cox regression models. *Sci Rep.* (2023) 13:18498. doi: 10.1038/s41598-023-45831-8

14. Xiu W, Zheng J, Zhou Y, Du H, Li J, Li W, et al. A nomogram for the prediction of the survival of patients with advanced non-small cell lung cancer and interstitial lung disease. *Cancer Med.* (2023) 12:11375–84. doi: 10.1002/cam4.5852

15. Jiang M, Li C, Tang S, Lv W, Yi A, Wang B, et al. Nomogram based on shearwave elastography radiomics can improve preoperative cervical lymph node staging for papillary thyroid carcinoma. *Thyroid*. (2020) 30:885–97. doi: 10.1089/thy.2019.0780

16. Wang X, Feng J, Li Z, Zhang X, Chen J, Feng G. Characteristics and prognosis of embryonal rhabdomyosarcoma in children and adolescents: An analysis of 464 cases from the SEER database. *Pediatr Investig.* (2020) 4:242–9. doi: 10.1002/ped4.12220

17. Liang W, Li L, Wang M, Liu Y, Qiu Y, Zhang B, et al. Non-inferior efficacy of non-surgical treatment to surgical treatment in patients with nonmetastatic head and neck rhabdomyosarcoma: a SEER-based study. *Clin Transl Oncol.* (2023) 25:1779–92. doi: 10.1007/s12094-023-03076-x

 Yang L, Takimoto T, Fujimoto J. Prognostic model for predicting overall survival in children and adolescents with rhabdomyosarcoma. *BMC Cancer.* (2014) 14:654. doi: 10.1186/1471-2407-14-654

19. Xing KL, Lu LH, Huang X, He CB, Song YD, Guo RP, et al. A novel prognostic nomogram for patients with recurrence of intrahepatic cholangiocarcinoma after initial surgery. *Front Oncol.* (2020) 10:434. doi: 10.3389/fonc.2020.00434

20. Zhao K, Liu L, Zhou X, Wang G, Zhang J, Gao X, et al. Re-exploration of prognosis in type B thymomas: establishment of a predictive nomogram model. *World J Surg Oncol.* (2024) 22:26. doi: 10.1186/s12957-023-03293-2

21. Radzikowska J, Kukwa W, Kukwa A, Czarnecka AM, Kawecki M, Lian F, et al. Management of pediatric head and neck rhabdomyosarcoma: A case-series of 36 patients. *Oncol Lett.* (2016) 12:3555–62. doi: 10.3892/ol.2016.5072

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

22. Sultan I, Qaddoumi I, Yaser S, Rodriguez-Galindo C, Ferrari A. Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2,600 patients. *J Clin Oncol.* (2009) 27:3391–7. doi: 10.1200/jco.2008.19.7483

23. Maurer HM, Moon T, Donaldson M, Fernandez C, Gehan EA, Hammond D, et al. The intergroup rhabdomyosarcoma study: a preliminary report. *Cancer*. (1977) 40:2015–26. doi: 10.1002/1097-0142(197711)40:5<2015::aid-cncr2820400505>3.0.co;2-k

24. Ahmad Z, Din NU, Ahmad A, Imran S, Pervez S, Ahmed R, et al. Rhabdomyosarcoma-an epidemiological and histopathologic study of 277 cases from a major tertiary care center in Karachi, Pakistan. *Asian Pac J Cancer Prev.* (2015) 16:757–60. doi: 10.7314/apjcp.2015.16.2.757

25. Luu QC, Lasky JL, Moore TB, Nelson S, Wang MB. Treatment of embryonal rhabdomyosarcoma of the sinus and orbit with chemotherapy, radiation, and endoscopic surgery. J Pediatr Surg. (2006) 41:e15–7. doi: 10.1016/j.jpedsurg.2006.02.036

26. Ma X, Huang D, Zhao W, Sun L, Xiong H, Zhang Y, et al. Clinical characteristics and prognosis of childhood rhabdomyosarcoma: a ten-year retrospective multicenter study. *Int J Clin Exp Med.* (2015) 8:17196–205.

27. Hosoi H, Teramukai S, Matsumoto Y, Tsuchiya K, Iehara T, Hara J, et al. A review of 331 rhabdomyosarcoma cases in patients treated between 1991 and 2002 in Japan. *Int J Clin Oncol.* (2007) 12:137–45. doi: 10.1007/s10147-006-0638-6

28. Unsal AA, Chung SY, Unsal AB, Baredes S, Eloy JA. A population-based analysis of survival for sinonasal rhabdomyosarcoma. *Otolaryngol Head Neck Surg.* (2017) 157:142–9. doi: 10.1177/0194599817696292

29. Dantonello TM, Int-Veen C, Winkler P, Leuschner I, Schuck A, Schmidt BF, et al. Initial patient characteristics can predict pattern and risk of relapse in localized rhabdomyosarcoma. *J Clin Oncol.* (2008) 26:406–13. doi: 10.1200/jco.2007.12.2382

30. Chisholm JC, Marandet J, Rey A, Scopinaro M, de Toledo JS, Merks JH, et al. Prognostic factors after relapse in nonmetastatic rhabdomyosarcoma: a nomogram to better define patients who can be salvaged with further therapy. *J Clin Oncol.* (2011) 29:1319–25. doi: 10.1200/jco.2010.32.1984

31. Agaram NP. Evolving classification of rhabdomyosarcoma. *Histopathology*. (2022) 80:98–108. doi: 10.1111/his.14449

32. Reilly BK, Kim A, Peña MT, Dong TA, Rossi C, Murnick JG, et al. Rhabdomyosarcoma of the head and neck in children: review and update. *Int J Pediatr Otorhinolaryngol.* (2015) 79:1477–83. doi: 10.1016/j.ijporl.2015.06.032

33. Correa R, Gómez-Millán J, Lobato M, Fernández A, Ordoñez R, Castro C, et al. Radiotherapy in soft-tissue sarcoma of the extremities. *Clin Transl Oncol.* (2018) 20:1127–35. doi: 10.1007/s12094-018-1848-x

34. Perez EA, Kassira N, Cheung MC, Koniaris LG, Neville HL, Sola JE. Rhabdomyosarcoma in children: a SEER population based study. *J Surg Res.* (2011) 170:e243–51. doi: 10.1016/j.jss.2011.03.001

35. Komdeur R, Klunder J, van der Graaf WT, van den Berg E, de Bont ES, Hoekstra HJ, et al. Multidrug resistance proteins in rhabdomyosarcomas: comparison between children and adults. *Cancer*. (2003) 97:1999–2005. doi: 10.1002/cncr.11259

36. Williamson D, Missiaglia E, de Reyniès A, Pierron G, Thuille B, Palenzuela G, et al. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. *J Clin Oncol.* (2010) 28:2151–8. doi: 10.1200/jco.2009.26.3814

37. Davicioni E, Anderson MJ, Finckenstein FG, Lynch JC, Qualman SJ, Shimada H, et al. Molecular classification of rhabdomyosarcoma-genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group. *Am J Pathol.* (2009) 174:550–64. doi: 10.2353/ajpath.2009.080631

38. Arndt CA. Risk stratification of rhabdomyosarcoma: a moving target. Am Soc Clin Oncol Educ Book. (2013) 33:415–9. doi: 10.14694/EdBook_AM.2013.33.415

39. Hibbitts E, Chi YY, Hawkins DS, Barr FG, Bradley JA, Dasgupta R, et al. Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group. *Cancer Med.* (2019) 8:6437–48. doi: 10.1002/cam4.2504

40. Kim JR, Yoon HM, Koh KN, Jung AY, Cho YA, Lee JS. Rhabdomyosarcoma in children and adolescents: patterns and risk factors of distant metastasis. *AJR Am J Roentgenol.* (2017) 209:409–16. doi: 10.2214/ajr.16.17466

41. Turner JH, Richmon JD. Head and neck rhabdomyosarcoma: a critical analysis of population-based incidence and survival data. *Otolaryngol Head Neck Surg.* (2011) 145:967–73. doi: 10.1177/0194599811417063

42. Kana LA, Smith JD, Bellile EL, Chugh R, McKean EL. Surgical management of rhabdomyosarcoma of the nasal cavity and paranasal sinuses: analysis of operative indications, settings, and outcomes. *J Neurol Surg B Skull Base.* (2022) 83:350–8. doi: 10.1055/s-0041-1736590

43. Dasgupta R, Rodeberg DA. Update on rhabdomyosarcoma. Semin Pediatr Surg. (2012) 21:68–78. doi: 10.1053/j.sempedsurg.2011.10.007

44. Schoot RA, Theunissen EA, Slater O, Lopez-Yurda M, Zuur CL, Gaze MN, et al. Hearing loss in survivors of childhood head and neck rhabdomyosarcoma: a long-term follow-up study. *Clin Otolaryngol.* (2016) 41:276–83. doi: 10.1111/coa.12527

45. Puri DR, Wexler LH, Meyers PA, La Quaglia MP, Healey JH, Wolden SL. The challenging role of radiation therapy for very young children with rhabdomyosarcoma. *Int J Radiat Oncol Biol Phys.* (2006) 65:1177–84. doi: 10.1016/j.ijrobp.2006.02.014

46. Chan JY, Zhang Z, Chew W, Tan GF, Lim CL, Zhou L, et al. Biological significance and prognostic relevance of peripheral blood neutrophil-to-

lymphocyte ratio in soft tissue sarcoma. Sci Rep. (2018) 8:11959. doi: 10.1038/ s41598-018-30442-5

47. Vasquez L, León E, Beltran B, Maza I, Oscanoa M, Geronimo J. Pretreatment neutrophil-to-lymphocyte ratio and lymphocyte recovery: independent prognostic factors for survival in pediatric sarcomas. *J Pediatr Hematol Oncol.* (2017) 39:538–46. doi: 10.1097/mph.00000000000911

48. Szkandera J, Gerger A, Liegl-Atzwanger B, Absenger G, Stotz M, Friesenbichler J, et al. The lymphocyte/monocyte ratio predicts poor clinical outcome and improves the predictive accuracy in patients with soft tissue sarcomas. *Int J Cancer*. (2014) 135:362–70. doi: 10.1002/ijc.28677

49. Fausti V, De Vita A, Vanni S, Ghini V, Gurrieri L, Riva N, et al. Systemic inflammatory indices in second-line soft tissue sarcoma patients: focus on lymphocyte/ monocyte ratio and trabectedin. *Cancers (Basel)*. (2023) 15:1080. doi: 10.3390/ cancers15041080